Method and apparatus for inactivation of biological contaminants using photosensitizers
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61L-002/00
A01N-001/02
C12N-013/00
A61K-035/14
C07D-493/00
출원번호
US-0596429
(2000-06-15)
발명자
/ 주소
Goodrich, Jr.,Raymond Paul
Hlavinka,Dennis
출원인 / 주소
Gambro, Inc.
대리인 / 주소
Greenlee, Winner and Sullivan, P.C.
인용정보
피인용 횟수 :
16인용 특허 :
204
초록▼
Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in sai
Methods and apparatuses for treating fluids to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents are provided. The methods comprise adjusting the percentage of plasma in said fluid to a desired value; mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.
대표청구항▼
What is claimed is: 1. A method for treating a fluid to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents, said method comprising: (a) adjusting the percentage of plasma in
What is claimed is: 1. A method for treating a fluid to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents, said method comprising: (a) adjusting the percentage of plasma in said fluid to a desired value; (b) mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer with said fluid; (c) exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated. 2. The method of claim 1, wherein said mixing step occurs after said adjusting step. 3. The method of claim 1, wherein said adjusting step occurs after said mixing step. 4. The method of claim 1, wherein said adjusting step and said mixing step occur simultaneously. 5. The method of claim 1, wherein said adjusting step comprises adding a sufficient volume of a diluting solution to the fluid so that the percentage of plasma is at a desired value. 6. The method of claim 5, wherein said diluting solution is saline. 7. The method of claim 5, wherein said diluting solution is a buffer. 8. The method of claim 5, wherein said diluting solution includes nutrients. 9. The method of claim 8, wherein said diluting solution includes phosphate. 10. The method of claim 5, wherein said diluting solution is a cell storage solution. 11. The method of claim 5, wherein said diluting solution is an anticoagulant. 12. The method of claim 5, wherein said diluting solution is a cryopreservative solution. 13. The method of claim 1, wherein said adjusting step comprises washing the fluid. 14. The method of claim 13 including a plurality of washing steps. 15. The method of claim 1 wherein said photosensitizer is a photo-activatable compound whose photolytic products (if any) are of low or no toxicity to humans or animals. 16. The method of claim 15 wherein said photosensitizer is 7, 8-dimethyl-10-ribityl isoalloxazine. 17. The method of claim 1 wherein said microorganisms are selected from the group consisting of bacteria, bacteriophages, and intracellular and extracellular viruses. 18. The method of claim 1 wherein said microorganisms are bacteria. 19. The method of claim 1 wherein said microorganisms are selected from the group consisting of HIV viruses, hepatitis viruses, sindbis virus, cytomegalovirus, vesicular stomatitis virus, herpes simplex viruses, vaccinia virus, human T-lymphotropic retroviruses, HTLV-III, lymphadenopahy virus LAV/IDAV, parvovirus, transfusion-transmitted (TT) virus, Epstein-Barr virus, bacteriophages ΦX174, Φ6, λ , R17, T4, T2, P. aeruginosa, S. aureus, S. epidermidis, L. monocytogenes, E. coli K. pneumoniae and S. marcescens. 20. The method of claim 1 wherein said photoradiation is light in the visible spectrum. 21. The method of claim 1, wherein said photoradiation is light in the ultraviolet spectrum. 22. The method of claim 1, wherein said photoradiation is light in both the visible and ultraviolet spectra. 23. The method of claim 22, wherein about half the light is in the visible spectrum and about half the light is in the ultraviolet spectrum. 24. The method of claim 22, wherein about one third of the light is in the visible spectrum and about two thirds of the light is in the ultraviolet spectrum. 25. The method of claim 22, wherein about two thirds of the light is in the visible spectrum and about one third of the light is in the ultraviolet spectrum. 26. The method of claim 1, wherein said photoradiation is of sufficient wavelength to activate 7,8-dimethyl-10-ribityl isoalloxazine in the fluid. 27. The method of claim 1, wherein the percentage of plasma in said fluid is adjusted to be within about 0 to about 50 percent of the total volume of said fluid when said fluid contains platelets, red blood cells, or a combination of both. 28. The method of claim 1, wherein the percentage of plasma in said fluid is adjusted to be within about 0 to about 20 percent of the total volume of said fluid when said fluid contains platelets, red blood cells, or a combination of both. 29. The method of claim 1, wherein the percentage of plasma in said fluid is adjusted to be within about 0 to about 10 percent of the total volume of said fluid when said fluid contains platelets, red blood cells, or a combination of both. 30. The method of claim 1, wherein the percentage of plasma in said fluid is adjusted to be within about 99 to about 80 percent of the total volume of said fluid. 31. The method of claim 1 wherein said photosensitizer is added to anticoagulant and said anticoagulant is added to said fluid. 32. A method of claim 1 wherein an enhancer is added to said fluid prior to exposing said fluid to photoradiation. 33. A method of claim 32 wherein said enhancer is selected from the group consisting of adenine, histidine, cysteine, tyrosine, tryptophan, ascorbate, N-acetyl-L-cysteine, propyl gallate, glutathione, mercaptopropionylglycine, dithiothreotol, nicotinamide, BHT, BHA, lysine, serine, methionine, glucose, mannitol, trolox, glycerol, and mixtures thereof. 34. The method of claim 1 wherein said exposing step comprises flowing the fluid containing said photosensitizer past a source of photoradiation at a rate and depth selected to ensure penetration of the photoradiation through the fluid and inactivation of the microorganisms. 35. The method of claim 1 wherein said fluid and photosensitizer are contained in a container transparent to said photoradiation. 36. The method of claim 35 further comprising agitating said container during said exposing step. 37. The method of claim 1 wherein said adding step further comprises placing said fluid in a container transparent to said photoradiation, adding said photosensitizer to said fluid in powder form, and agitating said container. 38. The method of claim 37, wherein said percentage of plasma is adjusted before placing said fluid in said container. 39. The method of claim 37, wherein said percentage of plasma is adjusted after placing said fluid in said container. 40. The method of claim 37, wherein said percentage of plasma is adjusted simultaneously with placing said fluid in said container. 41. The method of claim 37, further comprising adding nutrients in powder form to said container. 42. The method of claim 37 wherein said nutrients and photosensitizer are present in the container prior to addition of said fluid. 43. The method of claim 1 wherein said fluid comprises blood constituents. 44. The method of claim 1 wherein said fluid comprises whole blood. 45. The method of claim 1 wherein said fluid comprises a separated blood product. 46. The method of claim 1 wherein said fluid consists essentially of platelets. 47. The method of claim 1 wherein said fluid consists essentially of serum. 48. The method of claim 1 wherein said fluid consists essentially of plasma. 49. The method of claim 1 wherein said fluid consists essentially of red blood cells. 50. The method of claim 1 wherein said fluid comprises a therapeutic protein composition. 51. The method of claim 1 wherein said fluid contains a biologically-active protein selected from the group consisting of: factor VIII, Von Willebrand factor, factor IX, factor X, factor XI, Hageman factor, prothrombin, anti-thrombin III, fibronectin, plasminogen, plasma protein fraction, peritoneal dialysis solutions, immune serum globulin, modified immune globulin, albumin, plasma growth hormone, somatomedin, plasminogen streptokinase complex, ceruloplasmin, transferrin, haptoglobin, antitrypsin and prekallikrein. 52. The method of claim 1 wherein the activity of a biologically-active protein in said fluid is at a biologically-active level after said exposing step. 53. A blood product comprising inactivated microorganisms and endogenous photosensitizer or endogenously-based derivative photosensitizer and a lowered plasma content than occurs naturally, made by the method of claim 1. 54. A method for treating a fluid containing platelets to inactivate microorganisms which may be present therein, said method comprising: (a) mixing an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer with a fluid which contains platelets and a plasma content of between about 0% to about 50% of the total volume of the fluid; (b) exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated. 55. The method of claim 54, wherein said fluid contains a plasma content between about 0 to about 25% of the total volume of said fluid. 56. The method of claim 54, wherein said fluid contains plasma at a volume of less than 25% of the total volume of said fluid. 57. The method of claim 54, wherein said method further comprises: adding sufficient additives to the fluid so that one or more proteins present in said fluid remains biologically active after said exposing step. 58. The method of claim 54, wherein said photosensitizer is 7, 8-dimethyl-10-ribityl isoalloxazine. 59. The method of claim 54, wherein said photosensitizer is present at a concentration of between about 1 to about 200 micromolar. 60. The method of claim 54, wherein said photoradiation is between about 400 and about 500 nm. 61. The method of claim 54, wherein said photoradiation is between about 100 and about 500 J/cm2. 62. The method of claim 54, wherein said photoradiation is between about 100 and about 200 J/cm2. 63. A method for treating a fluid containing red blood cells to inactivate microorganisms which may be present therein, said method comprising: (a) adding an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer to a fluid which contains red blood cells and a plasma content of between about 0% to about 50% of the total volume of said fluid; (b) exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated. 64. The method of claim 63, wherein said plasma content in said fluid is less than about 10% of the total volume of said fluid. 65. The method of claim 63, wherein said plasma content is less than about 5% of the total volume of said fluid. 66. The method of claim 63, wherein said photosensitizer is 7, 8-dimethyl-10-ribityl isoalloxazine. 67. The method of claim 63, wherein said photosensitizer is present at a concentration of between about 1 to about 200 micromolar. 68. The method of claim 63, wherein said photosensitizer is present at a concentration of between about 50 to about 150 micromolar. 69. The method of claim 63, wherein said photoradiation is between about 420 and about 500 nm. 70. The method of claim 63, wherein said photoradiation is between about 100 and about 500 J/cm2. 71. The method of claim 63, wherein said photoradiation is between about 50 and about 200 J/cm2. 72. A method for treating a fluid containing plasma to inactivate microorganisms which may be present therein, said method comprising: (a) adding an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer to a fluid having a plasma content of between about 60% to about 100% of the total volume of said fluid; (b) exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated. 73. The method of claim 72, wherein said fluid contains about 90% or less plasma by volume. 74. The method of claim 72, wherein said photosensitizer is 7, 8-dimethyl-10-ribityl isoalloxazine. 75. The method of claim 72, wherein said photosensitizer is present at a concentration of between about 5 to about 15 micromolar. 76. The method of claim 72, wherein said photoradiation is between about 300 and about 500 nm. 77. The method of claim 72, wherein said photoradiation is between about 100 and about 500 J/cm2. 78. The method of claim 72, wherein said photoradiation is between about 300 and about 500 J/cm2. 79. An apparatus for inactivating microorganisms which may be present in a fluid, said fluid having a portion of the plasma removed, with an endogenous or endogenously-based derivative photosensitizer, comprising: (a) a source of light that emits light of a suitable wavelength and intensity to activate the endogenous or endogenously-based derivative photosensitizer; (b) means for maintaining the fluid and an effective amount of an endogenous or endogenously-based derivative photosensitizer in the light path for a sufficient time to achieve the desired level of inactivation. 80. The apparatus of claim 79, wherein said means for maintaining the fluid and an effective amount of an endogenous or endogenously-based derivative photosensitizer in the light path comprises a support surface substantially parallel to said source of light. 81. The apparatus of claim 79, wherein said light source comprises one or more light emitting diodes. 82. The apparatus of claim 81, wherein said light emitting diodes emit light in the visible range of the spectrum. 83. The apparatus of claim 79, wherein said fluid comprises blood or blood components. 84. The apparatus of claim 79, wherein said photosensitizer is 7,8-dimethyl-10-ribityl isoalloxazine. 85. A system for treating a fluid to inactivate microorganisms which may be present therein with an endogenous or endogenously based photosensitizer comprising: (a) a container comprising said fluid having a reduced level of plasma, at least an effective amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer, and optionally one or more additives, said container having a surface sufficiently photopermeable to allow exposure of the fluid therein to an amount of photoradiation sufficient to activate the photosensitizer; (b) at least one photoradiation source in light communication with said container, said source capable of generating a suitable wavelength and intensity to activate the endogenous photosensitizer or endogenously-based derivative photosensitizer whereby microorganisms present are inactivated. 86. The system of claim 85, wherein said photosensitizer is 7, 8-dimethyl-10-ribityl isoalloxazine. 87. The system of claim 85 wherein said photoradiation source provides light in the visible spectrum. 88. The system of claim 85, wherein said photoradiation source provides light in the ultraviolet spectrum. 89. The system of claim 85, wherein said photoradiation source provides light in both the visible and ultraviolet spectrum. 90. The system of claim 85 also comprising a photoradiation enhancer. 91. The system of claim 90 wherein said photoradiation enhancer comprises a reflective surface. 92. The system of claim 85 comprising a light guide for conducting photoradiation from said photoradiation source to said photopermeable container. 93. The system of claim 85 also comprising a temperature monitor. 94. The system of claim 85 also comprising one or more temperature controllers. 95. The system of claim 94 wherein said temperature controller is a fan directed so as to cool the light source and/or the fluid. 96. The system of claim 85 also comprising means for flowing said fluid into and out of said container. 97. The system of claim 85 also comprising means for agitating said fluid. 98. A system for inactivation of microorganisms in a fluid containing such microorganisms comprising: (a) means for adjusting the plasma content of said fluid; (b) means for mixing an effective amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer with said fluid in fluid communication with said means for adjusting the plasma content of said fluid; (c) a photopermeable container for said fluid in fluid communication with said means for adding photosensitizer and said means for adjusting the plasma content having a depth and length selected to allow exposure of the fluid of step (b) therein to an amount of photoradiation sufficient to activate the photosensitizer at a selected flow rate; (d) means for producing said selected flow rate of said fluid through said container; and (e) at least one photoradiation source in light communication with said container, said source capable of providing sufficient photoradiation to the fluid in said container of a type and amount selected to activate the photosensitizer. 99. A system for treating a fluid to inactivate microorganisms which may be present therein comprising: (a) means for adjusting the percentage of plasma in said fluid; (b) means for adding an effective amount of endogenous or endogenously-based photosensitizer to said fluid; (c) a photopermeable container for said fluid of depth which allows exposure of the fluid to an amount of photoradiation sufficient to activate the photosensitizer; (d) means for agitating said container; (e) at least one photoradiation source for providing sufficient photoradiation to the fluid in said container of a type and amount selected to activate the photosensitizer. 100. The system of claim 99 wherein said photopermeable container is a transparent plastic bag. 101. The system of claim 100 wherein said photopermeable container is a transparent rigid plastic container. 102. The system of claim 99 wherein said means for agitating said container comprises a shaker table. 103. The system of claim 99 wherein said photopermeable container contains said photosensitizer prior to addition of said fluid. 104. The system of claim 99 wherein said means for adjusting the level of plasma in said fluid comprises a suitable amount of a solution contained in said container. 105. A method for collecting a fluid with reduced levels of microorganisms that may be present therein, said fluid containing one or more members of the group consisting of: blood and blood components, comprising: (a) placing said fluid in a photopermeable container; (b) adding an endogenous or endogenously-based derivative photoactive material to said container; (c) adjusting the level of plasma in said fluid to a desired level; (d) exposing said fluid to radiation of a sufficient wavelength and intensity to activate said photoactive material, whereby microorganisms are inactivated. 106. The method of claim 105 wherein said photoactive material is present in said container prior to placing said fluid therein. 107. An apparatus for collecting a fluid with reduced levels of microorganisms that may be present therein, said fluid containing one or more members of the group consisting of: blood and blood components, comprising: (a) a photopermeable container containing an endogenous or endogenously-based derivative photoactive material and a suitable volume of a solution for adjusting the level of plasma in the fluid to a desired level; (b) a light source in light communication with said container that emits light of a suitable wavelength and intensity to inactivate microorganisms which may be present in said fluid. 108. A method for treating a fluid to inactivate microorganisms which may be present therein, said fluid containing one or more components selected from the group consisting of protein, blood and blood constituents, said method comprising: (a) removing a desired amount of the bilirubin present in the fluid; (b) adding an inactivation-effective, substantially non-toxic amount of an endogenous photosensitizer or endogenously-based derivative photosensitizer to said fluid; (c) exposing said fluid to photoradiation of sufficient wavelength and energy to activate the photosensitizer, whereby said microorganisms are inactivated.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (204)
Graham Donald W. (Mountainside NJ) Rogers Edward F. (Middletown NJ), 7-Methyl-8-methylamino-10-(1′-D-ribityl)isoalloxazine.
Wahl Terry R. (Englewood CO) Garrison Denise C. (Bailey CO) Steele Chad C. (Littleton CO) Gordon Timothy M. (Littleton CO) Hoard David W. (Carlsbad CA) Cruz Edward V. (Newbury Park CA), Apheresis blood processing method using pictorial displays.
Wolf ; Jr. Ludwig (Barington IL) Bratten William (Lake Villa IL) Foley John (Wheeling IL), Apparatus and method for inactivating viral contaminants in body fluids.
Vari Sandor G. (Van Nuys CA) Papazoglou Theodore (Athens CA GBX) Grundfest Warren S. (Los Angeles CA), Apparatus and method of use for a photosensitizer enhanced fluorescence based biopsy needle.
Ullman Edwin F. (Atherton CA) Kirakossian Hrair (San Jose CA) Pease John S. (Los Altos CA) Daniloff Yuri (Mountain View CA) Wagner Daniel B. (Sunnyvale CA), Assay method utilizing photoactivated chemiluminescent label.
Zelmanovic David ; Colella Gregory M. ; Hetherington Edward J. ; Chapman Evelyn Sabrinah ; Paseltiner Lynn, Automated method and device for identifying and quantifying platelets and for determining platelet activation state usi.
Bordeleau Joseph Raymond Luc,CAX ; Hastings David John,CAX ; McGarrity Michael Jerome,CAX, Beer having increased light stability and process of making.
Kahn Richard A. (St. Louis MO) Rodey Glenn E. (Chesterfield MO), Biocompatible method for in situ production of functional platelets and product produced thereby lacking immunogenicity.
Wollowitz Susan (Walnut Creek CA) Isaacs Stephen T. (Orinda CA) Rapoport Henry (Berkeley CA) Spielmann Hans Peter (Berkeley CA), Compounds for the photo decontamination of pathogens in blood.
Wollowitz Susan (Walnut Creek CA) Isaacs Stephen T. (Orinda CA) Rapoport Henry (Berkeley CA) Spielmann Hans P. (Berkeley CA) Nerio Aileen (Santa Clara CA), Compounds for the photodecontamination of pathogens in blood.
Bender Dean R. (Hazlet NJ) Hearst John E. (Berkeley CA) Rapoport Henry (Berkeley CA), Coumarin derivatives and method for synthesizing 5′-methyl psoralens therefrom.
Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Wright Meredith (San Jose CA), DNA photocleavage using texaphyrins.
Hearst David P. (1747 29th Ave. San Francisco CA 94122) Cimino George D. (1435 Liberty St. El Cerrito CA 94530) Hearst John E. (101 Southampton Ave. Berkeley CA 94707) Isaacs Stephen T. (79 Loma Vist, Device and method for photoactivation.
Hearst David P. (Redwood City CA) Cimino George D. (Richmond CA) Hearst John E. (Berkeley CA) Isaacs Stephen T. (Orinda CA), Device and method for photoactivation.
Valinsky Jay E. (New York NY) Reich Edward (New York NY) Easton Thomas G. (New York NY), Employment of a mereyanine dye for the detection of malignant leukocytic cells.
Budowsky Edward I. ; Gavrilov Alexander E.,RUX ITX 103055 ; Pivasyan Arman D., Enzymatic synthesis of 2',5'-oligoadenylate-2',3'-cyclophosphates and treatment of papillomaviruses.
Bode Arthur P. (Greenville NC) Heaton William A. L. (Norfolk VA) Holme Stein (Virginia Beach VA) Miller David T. (Parkland FL), Extended shelf life platelet preparations and process for preparing the same.
Hakky Said I. (8547 Merrimoor Blvd. ; E. Largo FL 34647-3145) Hakki A-Hamid (8547 Merrimoor Blvd. ; E. Largo FL 34647-3145) Hudson Perry B. (2225 Park St. ; North St. Petersburg FL 33710), Extracorporeal virioncidal apparatus.
Baccichetti Francarosa (Padua ITX) Bordin Franco (Padua ITX) Carlassare Francesco (Padua ITX) Dall\Acqua Francesco (Padua ITX) Guiotto Adriano (Padua ITX) Pastorini Giovanni (Padua ITX) Rodighiero Gi, Furocoumarin for the photochemotherapy of psoriasis and related skin diseases.
Villeneuve Luc,CAX ; Miller Gerard,CAX ; Bernier Robert,CAX ; Laurendeau Claude,CAX ; Pal Prabir Kumar,INX, Irradiating apparatus using a scanning light source for photodynamic treatment.
Lee Kyu H. (King of Prussia PA) Troutner Vernon H. (St. Petersburg FL) Goss Jack (Clearwater FL) King Martin J. (Seminole FL), Irradiation chamber for photoactivation patient treatment system.
Miripol Jeffrey E. (Newark DE) Bilstad Arnold (Deerfield IL) Foley John (Wheeling IL) Glash Dean (McHenry IL) Bratten William R. (Lake Villa IL), Irradiation of blood products.
Oseroff Allan (Brookline MA) Foley James (Andover MA) Cincotta Louis (Andover MA) Parrish John A. (Weston MA), Light-induced killing of carcinoma cells.
Chapman John R. ; Stark Peter R. H. ; Reed Michael A. ; Larson Dale N. ; Cuffaro Daniel F., Method and apparatus for inactivating contaminants in biological fluid.
Goodrich ; Jr. Raymond Paul ; Corbin ; III Frank ; Wood ; Jr. Edward C., Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers.
Goodrich ; Jr. Raymond Paul ; Hlavinka Dennis ; Corbin ; III Frank ; Wood ; Jr. Edward C., Method and apparatus for inactivation of biological contaminants using photosensitizers.
Mller Gerhard (Berlin DEX) Mller-Stolzenburg Norbert (Berlin DEX), Method and apparatus for performing surgery on tissue wherein a laser beam is applied to the tissue.
Eckhouse Shimon (Haifa ILX) Kreindel Michael (Haifa ILX), Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment.
Ury Michael G. (Bethesda MD) Phillips John T. (Gaithersburg MD), Method and apparatus for treating fluids by focusing reflected light on a thin fluid layer.
Alfano Robert R. (3777 Independence Ave. Bronx NY 10463) Alfano Michele A. (3777 Independence Ave. Bronx NY 10463), Method for detecting cancerous tissue using visible native luminescence.
Judy Millard M. (Dallas TX) Matthews James L. (Dallas TX) Newman Joseph T. (Dallas TX) Sogandares-Bernal Franklin (Dallas TX), Method for eradicating infectious biological contaminants in body tissues.
Judy Millard M. (Dallas TX) Matthews James L. (Dallas TX) Newman Joseph T. (Dallas TX) Sogandares-Bernal Franklin (Dallas TX), Method for eradicating infectious biological contaminants in body tissues.
Wollowitz Susan (Walnut Creek CA) Isaacs Stephen T. (Orinda CA) Rapoport Henry (Berkeley CA) Spielmann Hans P. (Lexington KY) Nerio Aileen (Santa Clara CA), Method for inactivating pathogens in blood using photoactivation of 4′-primary amino-substituted psoralens.
Chapman John (Lake Villa IL) Logan Patricia M. (Vancouver CAX) Neyndorff Herma C. (Vancouver CAX) North Janice (Vancouver CAX), Method for inactivating pathogens in compositions containing cells and plasma using photoactive compounds and plasma pro.
Chapman John (Lake Villa IL) Logan Patricia M. (Vancouver British Columbia CAX) Neyndorff Herma C. (Vancouver British Columbia CAX) North Janice (Vancouver British Columbia CAX), Method for inactivating pathogens in erythrocytes using photoactive compounds and plasma protein reduction.
Wollowitz Susan (Walnut Creek CA) Cook David (Walnut Creek CA) Nerio Aileen (Fremont CA), Method for inactivating pathogens in red cell compositions using quinacrine mustard.
Hearst David P. (San Francisco CA) Cimino George D. (El Cerrito CA) Hearst John E. (Berkeley CA) Isaacs Stephen T. (Orinda CA), Method for photoactivation.
Moake Joel L. (Houston TX) Phillips Martin D. (Houston TX) McIntire Larry V. (Houston TX) Hellums Jesse D. (Houston TX), Method for preventing and treating thrombosis.
Wollowitz Susan ; Isaacs Stephen T. ; Rapoport Henry ; Spielmann Hans Peter ; Nerio Aileen, Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens.
Goodrich ; Jr. Raymond P. (Pasadena CA) Platz Matthew S. (Columbus OH) Yerram Nagender (South Pasadena CA) Hackett Roger W. (Pasadena CA) van Borssum Waalkes Marjan (Vernendaal NLX) Williams-Hughes C, Method of inactivation of viral and bacterial blood contaminants.
Park Sang Chul ; Goodrich ; Jr. Raymond P. ; Yerram Nagender ; Sowemimo-Coker Samuel O. ; Platz Matthew S. ; Aquila Brian M., Method of inactivation of viral and bacterial blood contaminants.
Park Sang Chul ; Goodrich ; Jr. Raymond P. ; Yerram Nagender ; Sowemimo-Coker Samuel O. ; Platz Matthew S. ; Aquila Brian M., Method of inactivation of viral and bacterial blood contaminants.
Platz Matthew S. (Columbus OH) Goodrich ; Jr. Raymond P. (Pasadena CA) Yerram Nagendar (South Pasadena CA), Method of inactivation of viral and bacterial blood contaminants.
Sowemimo-Coker Samuel O. ; Yerram Nagender ; Goodrich ; Jr. Raymond P. ; Platz Matthew S., Method of inactivation of viral and bacterial blood contaminants.
Platz Matthew S. (Columbus OH) Goodrich ; Jr. Raymond P. (Pasadena CA) Wong Victoria A. (Cary NC), Method of inactivation of viral blood contaminants using acridine deriatives.
Mach ; deceased Walter (late of Kirchseon DEX) Mach ; legal representative by Chantal (Wasserburgerstr. 17 D-8011 Kirchseon DEX), Method of treating a patient suffering from a viral infection.
McCoy William F. (Naperville IL) Hoots John E. (St. Charles IL), Method of use of compositions of biocides and fluorescent indicators to control microbial growth.
Lin Lily (Berkeley CA) Corash Lawrence (Berkeley CA) Isaacs Stephen T. (Orinda CA) Hanson Carl V. (Berkeley CA) Cimino George D. (Richmond CA), Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen.
Fossel Eric T. (Chestnut Hill MA), Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents.
Horowitz Bernard (New Rochelle NY) Valinsky Jay E. (New York NY) Geacintov Nicholas E. (New York NY) Williams Bolanle (Forest Hills NY) Rywkin Shanti B. (Brooklyn NY), Photodynamic inactivation of viruses in blood cell-containing compositions.
Horowitz Bernard (New Rochelle NY) Valinsky Jay E. (New York NY) Geacintov Nicholas E. (New York NY) Williams Bolanle (New York NY) Rywkin Shanti B. (Brooklyn NY) Nunno Henrietta (New York NY), Photodynamic inactivation of viruses in cell-containing compositions.
Matthews J. Lester (Dallas TX) Judy Millard M. (Dallas TX) Newman Joseph T. (Dallas TX) Sogandares-Bernal Frank (Dallas TX) Sessler Jonathan L. (Austin TX) Harriman Anthony (Austin TX) Maiya Bhaskar , Photodynamic viral deactivation with sapphyrins.
Park Sang C. (Arcadia CA) Goodrich ; Jr. Raymond P. (Pasadena CA) Yerram Nagender (S. Pasadena CA) Sowemimo-Coker Samuel O. (Arcadia CA) Platz Matthew S. (Columbus OH) Aquila Brian M. (Painesville OH, Photoinactivation of viral and bacterial blood contaminants using halogenated coumarins.
Stanco Alexei (75A Angos Street Adelaide AUX 5000) Piper James A. (Macquarie Uni. ; North Ryde Sydney ; New South Wales AUX 2113), Photoradiation method and arrangement.
Shang Shaye-wen (Vernon Hills IL) Ling Michael Tung-Kiung (Vernon Hills IL) Woo Lecon (Libertyville IL) Cometa Christopher C. (Mundelein IL), Plastic formulations for platelet storage containers and the like.
Wiesehahn Gary P. (Alameda CA) Creagan Richard P. (Alta Loma CA) Stevens David R. (Fremont CA) Giles Richard (Alameda CA), Preparation of inactivated viral vaccines.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Reemtsma Keith (New York NY) Hardy Mark A. (Scarsdale NY) Lau Henry T. (New York NY), Process for development of acceptance of transplanted organs and tissues.
Lee Eric Kin-Lam (Acton MA) Fouron Yves (Marlborough MA) Castino Franco (Sudbury MA) Zepp Charles Melvyn (Hardwick MA) Azad Abdul R. M. (Northborough MA), Process for simultaneously removing leukocytes and methylene blue from plasma.
Dazey Bernard (Bordeaux FRX) Hamsany Mohamed (Bordeaux FRX) Enfedaque-Morer Sylvia (Bordeaux FRX), Process for the manufacture of a high-purity activated factor VII concentrate essentially free of vitamin K-dependent fa.
Margolis-Nunno Henrietta (New York NY) Ben-Hur Ehud (New York NY) Horowitz Bernard (New Rochelle NY), Process for the sterilization of biological compositions using UVA1 irradiation.
Horowitz Bernard ; Williams Bolanle ; Margolis-Nunno Henrietta ; Chin Sing N., Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photod.
Reemtsma Keith (New York NY) Hardy Mark A. (Scarsdale NY) Lau Henry T. (New York NY), Processes for development of acceptance of transplanted organs and tissues.
Bachynsky Maria O. (Nutley NJ) Infeld Martin H. (Upper Montclair NJ) Margolis Richard J. (Wayne NJ) Perla Dennis A. (Wayne NJ), Psoralen reagent compositions for extracorporeal treatment of blood.
Eibl Johann (Vienna ATX) Schwarz Hans Peter (Vienna ATX) Siekmann Jurgen (Vienna ATX) Turecek Peter (Vienna ATX), Stable preparation for the treatment of blood coagulation disorders.
Lin Lily (Berkeley CA) Corash Lawrence (Berkeley CA) Isaacs Stephen (Orinda CA) Cimino George (Richmond CA), Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsora.
Lin Lily (Berkeley CA) Corash Laurence (San Francisco CA), Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen.
Holme Stein (Virginia Beach VA) Heaton William A. L. (Norfolk VA), Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets.
Holme Stein (Virginia Beach VA) Heaton William A. L. (Norfolk VA), Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets.
Holme Stein (Virginia Beach VA) Heaton William A. L. (Norfolk VA), Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets.
D\Silva Edmund D. (Vernon Hills IL), System to identify bags disinfected by irradiation which punches holes in a polarized portion of the bag to indicate pro.
Bischof Daniel F. (McHenry IL) Wolf ; Jr. Ludwig (Inverness IL) Foley John T. (Wheeling IL) Bratten William R. (Lake Villa IL), Systems and methods for eradicating contaminants using photoactive materials in fluids like blood.
Wolf ; Jr. Ludwig ; Foley John T. ; Bratten William R. ; Kunz Gary,CAX ; Stonefield Michael,CAX, Systems and methods for eradicating contaminants using photoactive materials in fluids like blood using discrete source.
Bischof Daniel F. (McHenry IL), Systems and methods for simultaneously removing free and entrained contaminants in fluids like blood using photoactive t.
Wolf ; Jr. Ludwig (Inverness IL) Foley John T. (Wheeling IL) Bratten William R. (Lake Villa IL), Systems for eradicating contaminants using photoactive materials in fluids like blood.
Chapman John R. ; Mathias Jean M.,BEX, Systems for quantifying the illumination characteristics of vessels such as blood processing containers with respect to.
Klainer Albert S. (315 W. 70th St. New York NY 10023) Bisaccia Emil (4 Sunnybrook Rd. Basking Ridge NJ 07920), Treatment methods and vaccines for stimulating an immunological response against retroviruses.
Bolton James R. (London CAX) Cater Stephen R. (Willowdale CAX), Treatment of contaminated waste waters and groundwaters with photolytically generated hydrated electrons.
Furumoto Horace W. (Wellesley MA) Ceccon Harry L. (Boston MA) Rizzo Antonio G. (Nashua NH), Ultra-long flashlamp-excited pulse dye laser for therapy and method therefor.
Hlavinka, Dennis J.; Goodrich, Raymond P.; Reddy, Heather, Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light.
Goodrich,Raymond P.; Platz,Matthew S.; Martin,Christopher B., Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.